The 2 Minute Medicine Podcast Episode 1
Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this ...
Tag: multiple sclerosis
The Scan by 2 Minute Medicine®: The Last Dance, Head of State, Trouble on the Farm and the Heart of COVID-19!
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
Ublituximab lowers incidence of relapse and number of brain lesions in relapsing multiple sclerosis
1. Two randomized clinical trials showed that intravenous ublituximab reduced relapse rate and the number of brain lesions in multiple ...
United States medical cannabis registration increased significantly between 2016 and 2020
1. Registration for medical cannabis increased 4.5 times from 2016 to 2020 in the United States, with chronic pain and ...
Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis
1. This cohort study found that younger age, spinal cord involvement, and gadolinium-enhancing lesions on magnetic resonance imaging were associated ...
Differences in national strategies for the treatment of relapsing-remitting multiple sclerosis significantly associated with disability outcomes during follow-up
1. The use of highly effective disease-modifying treatments for relapsing-remitting multiple sclerosis was significantly more prevalent in Swedish patients compared ...
Improvements in therapeutic and managing standards associated with significant reduction in risk of persistent disability in patients with pediatric-onset multiple sclerosis
1. In recent years, the risk of persistent disability has been significantly reduced in patients with pediatric-onset multiple sclerosis (POMS), ...
Ponesimod may be superior to teriflunomide for relapsing multiple scleorsis
1. Ponesimod was superior to teriflunomide for relapsing multiple sclerosis, in terms of reducing relapse rates, unique active lesions on ...
#VisualAbstract: Ofatumumab vs. teriflunomide for multiple sclerosis
1. In this double-blind, randomized phase 3 trial, patient treated with ofatumumab had a lower annualized relapse rate in multiple ...
Ofatumumab may reduce annual relapse rates compared to teriflunomide in multiple sclerosis
1. In this double-blind, randomized phase 3 trial, patient treated with ofatumumab had a lower annualized relapse rate in multiple ...